Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer.

Lissoni P, Rovelli F, Brivio F, Zago R, Colciago M, Messina G, Mora A, Porro G.

In Vivo. 2009 Jan-Feb;23(1):171-5.

2.
3.
4.

Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology.

Lissoni P, Fumagalli L, Brivio F, Rovelli F, Messina G, Di Fede G, Colciago M, Brera G.

J Biol Regul Homeost Agents. 2006 Jan-Jun;20(1-2):29-35.

PMID:
18088552
5.

Is there a role for melatonin in supportive care?

Lissoni P.

Support Care Cancer. 2002 Mar;10(2):110-6. Epub 2001 Nov 13. Review.

PMID:
11862501
6.

Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.

Lissoni P, Barni S, Mandalà M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G.

Eur J Cancer. 1999 Nov;35(12):1688-92.

PMID:
10674014
8.
10.

The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.

Matsushita H, Tsuboi K, Honda I, Kato N, Okochi O, Kobayashi D, Hattori M.

Gan To Kagaku Ryoho. 2009 May;36(5):797-801.

PMID:
19461180
11.

Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.

Lissoni P, Malugani F, Brivio F, Piazza A, Vintimilla C, Giani L, Tancini G.

Neuro Endocrinol Lett. 2003 Jun-Aug;24(3-4):259-62.

PMID:
14523367
12.

Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin.

Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A, Maestroni G.

Support Care Cancer. 1997 Mar;5(2):126-9.

PMID:
9069612
13.

Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.

Lissoni P, Rovelli F, Frassineti A, Fumagalli L, Malysheva O, Conti A, Maestroni G.

Neuro Endocrinol Lett. 2000;21(4):319-323.

PMID:
11455367
14.

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.

Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S.

Oncologist. 2009 Oct;14(10):995-1002. doi: 10.1634/theoncologist.2009-0083. Epub 2009 Sep 23.

15.

A spiritual approach in the treatment of cancer: relation between faith score and response to chemotherapy in advanced non-small cell lung cancer patients.

Lissoni P, Messina G, Parolini D, Balestra A, Brivio F, Fumagalli L, Vigore L, Rovelli F.

In Vivo. 2008 Sep-Oct;22(5):577-81.

16.

Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials.

O'Neil BH, Goldberg RM.

Oncologist. 2008 Oct;13(10):1074-83. doi: 10.1634/theoncologist.2008-0083. Epub 2008 Oct 15. Review.

17.

[Treatment outcome of locally advanced stage IIIA/B lung cancer].

Cicenas S, Zaliene A, Atkocius V.

Medicina (Kaunas). 2009;45(6):452-9. Lithuanian.

18.

Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.

Yasui H, Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N.

Jpn J Clin Oncol. 2009 May;39(5):315-20. doi: 10.1093/jjco/hyp014.

19.

Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.

Tribius S, Kronemann S, Kilic Y, Schroeder U, Hakim S, Schild SE, Rades D.

Strahlenther Onkol. 2009 Oct;185(10):675-81. doi: 10.1007/s00066-009-1992-x. Epub 2009 Oct 6.

PMID:
19806333
20.

A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971.

Coudert B, Focan C, Genet D, Giacchetti S, Cvickovic F, Zambelli A, Fillet G, Chollet P, Amoroso D, Van Der Auwera J, Lentz MA, Marreaud S, Baron B, Gorlia T, Biville F, Lévi F.

Chronobiol Int. 2008 Sep;25(5):680-96. doi: 10.1080/07420520802384036.

PMID:
18780198
Items per page

Supplemental Content

Write to the Help Desk